Aluboro

Quick links to important sections

Aluboro

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aluboro

What is Aluboro? Defining the Drug Entity and Its Class

Property Description
Active Ingredient Aluminum Acetate (C₆H₉AlO₆)
Form Powder for Topical Solution
Pharmacological Class Topical Astringent / Topical Antiseptic
General Purpose Soothing and drying wet, irritated skin
Origin Synthetic (Chemically derived solution)

Aluboro is a specific pharmaceutical preparation classified primarily as a topical astringent and a secondary topical antiseptic, designed for direct application to the skin's surface. Its true active component, formed upon reconstitution, is Aluminum Acetate Solution, which is historically and clinically recognized as Burow's Solution. This preparation belongs to a specialized group of agents widely used in dermatology that functions by inducing contraction or shrinkage of superficial skin tissues where applied, which is the definition of its primary action as an astringent. The use of Aluminum Acetate preparations to relieve minor skin irritations is established in pharmacological practice.


Composition and Form: The Synthesis of Aluminum Acetate

Aluboro is a combination product supplied as a powder for topical solution that must be mixed with an aqueous vehicle (water) before cutaneous administration. The unique feature of this preparation is that the final active ingredient, Aluminum Acetate, is synthetically derived in situ from a necessary chemical reaction between two precursor salts contained in the powder: Aluminium Sulphate and Calcium Acetate. This method of preparation ensures a freshly generated, highly functional solution is applied, unlike some pre-mixed solutions whose stability profiles may vary. The formation of Aluminum Acetate from these compounds is based on recognized chemical principles.


General Purpose: What Does Aluboro Fundamentally Do?

The general purpose of Aluboro, stemming from its designation as a topical astringent, is to provide effective relief for minor, localized skin irritations by promoting a powerful drying effect on the surface. By facilitating tissue contraction, the medication helps to physically reduce the weeping or oozing of fluids from small, damaged areas of skin, offering comfort in common scenarios such as minor environmental irritations. The resulting application of the solution also imparts a physical cooling effect, contributing to the immediate, temporary soothing of agitated or swollen areas without requiring systemic absorption.

Regulatory References

  1. Burow's Solution (NIH)

What side effects are possible with Aluboro?

Possible Side Effects and Safety Information

The safety profile for Aluminum Acetate topical solution (Aluboro) is primarily characterized by local effects at the application site, consistent with its function as a topical astringent. The adverse reactions documented in regulatory sources are generally confined to the Skin and Subcutaneous Tissue Disorders (Dermatological System-Organ Class).


Documented Localized Reactions

The most frequently documented adverse effects are local and transient in nature. These include skin irritation, skin inflammation, itching, and dryness. A temporary burning or stinging sensation may also be experienced acutely upon application. Regulatory documentation suggests that local irritation may occur within the 1% to 10% frequency range in some contexts, although specific frequencies are often not defined for these types of topical preparations.

Safety Constraints and Special Populations

Official labeling contains specific constraints related to application. The product is for external use only and is contraindicated in individuals with a known hypersensitivity to any of its components. Safety notes restrict application to open wounds and advise against contact with the eyes. Furthermore, the risk of excessive skin dryness (overdrying) is noted as a pattern associated with prolonged duration of use of the solution or wet dressing.

For specific populations, caution is advised. Aluminum Acetate is classified as Pregnancy Category C, meaning use is only considered if the potential benefit outweighs the potential risk to the fetus. For lactating women, caution is advised as it is unknown if the substance is excreted in human breast milk; application to the nipple area should be avoided.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory overdose profile for Aluboro (Aluminum Acetate Solution) is defined primarily by the risk associated with oral ingestion, as the product is intended solely for cutaneous application. Official labeling states that swallowing the solution is the exposure circumstance cited as potentially harmful, while serious systemic side effects are documented as unlikely from appropriate topical use.

Documented Manifestations and Emergency Action

When an overdose is suspected, particularly following ingestion, regulatory bodies mandate that urgent medical assistance must be sought immediately. The explicit official instruction is to call a doctor or poison control center right away.

Clinical manifestations associated with acute systemic exposure to aluminum include gastrointestinal effects such as nausea and vomiting. Other manifestations documented in relevant toxicity literature include mouth ulcers and specific skin rashes.

In terms of clinical support, the official regulatory information confirms that no specific antidote is known for Aluminum Acetate overdose. Therefore, management is limited to professional symptomatic and supportive treatment. No population-specific overdose considerations are explicitly documented in the official product labeling.

Therapeutic Uses of Aluboro

Easing Acute Skin Discomfort: Main Uses and Benefits

Aluboro is commonly used across conditions presenting with episodic or fluctuating symptom patterns that cause skin distress. It is applied in contexts where temporary, supportive symptom management is appropriate to address symptoms related to inflammatory or irritative states on the skin's surface. The application is relevant in areas where short-term symptom management is needed.

This includes managing the immediate discomfort of intense itching, burning sensations, redness, and swelling associated with acute reactions. The medication supports patients during episodes of heightened discomfort from common irritations like poison ivy, insect bites, or exposure to irritant chemicals. It is relevant for managing symptoms that interfere with daily comfort, particularly in cases involving fluid-related manifestations.

Quick Facts: Symptomatic Relief

  • Relief Domain: Primarily helps manage acute surface inflammation and irritation.
  • Key Symptom Groups: Used to address symptom clusters that may become intense, such as itching, burning, and swelling.
  • Benefit: Provides supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Official Population Eligibility Rules

The regulatory profile for Aluboro (Aluminum Acetate Topical Solution) defines who can and cannot use the medicine primarily through absolute prohibitions and conditions for special populations, consistent with its status as an over-the-counter external agent.

Contraindications and Mandatory Restrictions

Group Official Regulatory Status
Hypersensitivity Absolute Contraindication: Use is strictly prohibited for individuals with a known allergy to Aluminum Acetate or any component in the formulation.
Route of Use External Use Only: Must not be ingested or applied to the eyes. Use is also restricted from deep puncture wounds, animal bites, and serious burns.

Age and Special Population Eligibility

Group Regulatory Eligibility Statement
Adults Permitted for use under standard labeled conditions.
Pediatric Patients Use is generally permissible, but regulatory documents advise that special care may be needed and recommend discussion with a healthcare provider.
Pregnant/Lactating Individuals Conditional Use: Use during pregnancy or while breastfeeding is restricted; official guidance advises seeking a healthcare professional’s advice due to insufficient human data.
Renal/Hepatic Impairment No Restrictions: No specific limitations are documented in the topical regulatory labeling, reflecting minimal systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aluboro (Aluminum Acetate Solution) is a topical medicine, and its official interaction profile is defined by minimal systemic absorption, which generally eliminates documented risk for systemic metabolic or transporter-based drug-drug interactions, such as those involving CYP enzymes or P-glycoprotein.

Regulatory documentation focuses on local pharmacodynamic interactions that affect the intended function of the solution at the site of application. These interactions fall into two categories: those that reinforce the local effect and those that reduce efficacy.

Documented Topical Product Interactions

Interaction Type Interacting Product Category Regulatory Restriction
Pharmacodynamic Reinforcement Other drying topical products (including those with alcohol) Restriction: Must not be applied concurrently due to risk of excessive drying and irritation.
Efficacy Reduction Soap Restriction: Concurrent use may reduce the intended astringent action.
Efficacy Reduction Topical Collagenase preparations Restriction: Avoid concomitant use on the same area due to potential for decreased collagenase efficacy.

No systemic medicinal products are explicitly classified as contraindicated combinations with Aluboro in the official interaction sections. The constraints placed on the product are solely related to the timing and choice of other topical agents applied to the same area.

Mechanism of Action

The primary mechanism of action involves the aluminum ion ( Al^3+), which acts as an astringent by directly binding to and causing the mild precipitation (coagulation) of exposed structural proteins, such as keratin, on the skin's surface. This action is defined by a physicochemical interaction with structural proteins and is strictly localized to the point of application.

The resulting coagulation causes a physical contraction and shrinking of the superficial tissue, including the protein structures that line the walls of the surrounding capillaries. This mechanical restriction reduces the diameter and permeability of these small blood vessels, physically limiting the outflow (exudation) of serous fluid and inflammatory mediators. The consequence of this restriction is the cessation of fluid exudation, which produces a drying effect and mechanically limits localized fluid accumulation.

The mechanism is functionally dependent on the chemical complementarity of its two precursor salts, Aluminium Sulphate and Calcium Acetate, which must react in situ when mixed with water to freshly generate the active Aluminum Acetate solution. This immediate availability of the Al^3+ ion ensures the required concentration for the binding and coagulation mechanism.

Dosage and Administration Information

Official Administration Guidelines for Aluboro

The administration of Aluboro follows specific protocols that govern its use as a topical astringent. The route of administration is topical for external application only. The product is supplied as a powder that requires mandatory reconstitution before use.

Preparation and Dosing

The preparation involves dissolving one to three packets of the powder in approximately 473 milliliters (16 fluid ounces) of cool or warm water. This specific dilution process is necessary to chemically form the active agent, Aluminum Acetate Solution, resulting in a final concentration within the recognized range of 0.13% to 0.5%.

Application and Schedule

The solution is administered via two primary methods: as a wet dressing/compress or as an area soak. The schedule dictates that each application should last for 15 to 30 minutes. While wet dressings may be reapplied as needed, the soaking regimen is limited to a maximum frequency of three times daily. Application guidelines, including dilution ratios and frequency, are generally consistent for both adults and pediatric patients.

A critical procedural constraint is the requirement that the application must not be covered with any occlusive material, such as plastic, a rule essential for facilitating the evaporative drying action of the astringent. Additionally, the prepared solution must be discarded after each use. The overall use pattern is short-term, with application intended to be discontinued if the treated condition persists beyond seven days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aluboro (Aluminum Acetate Solution)


Evidence for Use in Weeping and Oozing Skin Conditions

The evidence supporting the evaluation of Aluboro for skin conditions that involve fluid leakage, such as severe poison ivy rashes or weeping eczema, relies primarily on its historical use record reviewed by regulators as a topical astringent. Instead of relying on numerous recent, large-scale clinical trials, its use was established through the review of historical data and consensus among expert advisory panels during the regulatory process.

Research has examined outcomes related to the solution's application on the skin, focusing on evaluating changes in weeping or oozing from the affected areas. Findings indicated patterns observed in the studies that are aligned with the physiologic principle underlying the solution, which is linked to drying and contraction principles. Evidence contributes to understanding symptom patterns by describing how patients reported outcomes related to physical discomfort symptoms like itching and stinging over short treatment durations.


Evidence for Use in Minor Skin Irritations and Acute Discomfort

Aluboro was studied in research exploring general, minor skin irritations, which are conditions characterized by fluctuating or episodic manifestations. This includes symptoms associated with insect bites, mild burns, or environmental rashes. Studies report how symptoms evolved in the observed populations over very short application intervals, consistent with monitoring outcomes linked to inflammatory or irritative states. A key area of observation was the evaluation of a localized cooling effect, which was associated with the solution's physical properties.

The research base for these minor complaints, while acknowledged from a regulatory standpoint, typically does not include recent, large-scale trials. Consequently, comparative evidence is lacking against many newer non-astringent alternatives.


What is Still Uncertain About Aluboro

Scientific and regulatory reviews describe several areas where the research evidence is limited or requires further study. The historical nature of the evidence indicates that the certainty level of findings is associated with established pharmacological principles and long-standing use, rather than recent, large-scale controlled trials. Data are still emerging regarding the precise role of the solution in complex, chronic skin conditions, and limited information is available for long-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Aluboro (FAQ)

Q: How quickly does Aluboro typically start working?

A: Aluboro is defined as a topical astringent, meaning it works through a physical process on the skin’s surface. According to the official mechanism of action, this physical action, which causes mild contraction and drying, is localized and is understood to occur upon contact with the skin.

Q: What is the longest period someone usually takes Aluboro for?

A: Official administration guidelines state that Aluboro is intended for short-term use. Regulatory guidance recommends that application should be discontinued if the treated condition or symptoms persist beyond seven days.

Q: Is there a generic version of Aluboro available?

A: The active ingredient, Aluminum Acetate solution, is historically and clinically recognized as an established chemical entity (Burow’s Solution). Because the active substance is non-proprietary, it is generally available under various brand names and as generic topical powder preparations.

Q: What is the official classification of Aluboro (e.g., controlled substance, prescription only)?

A: Regulatory documents classify the Aluminum Acetate solution as an Over-the-Counter (OTC) astringent drug product. Due to its topical use and safety profile, it is not classified as a controlled substance.

Q: Are there long-term side effects associated with Aluboro use?

A: Regulatory safety notes indicate that prolonged use may increase the potential for local effects, particularly excessive skin dryness or irritation at the application site. Official guidance limits the duration of application, advising discontinuation if the condition persists beyond seven days.

Q: Is Aluboro the same kind of drug as [Similar Drug Name]?

A: Aluboro is officially categorized as a topical astringent. This means its primary function is to cause physical drying and mild tissue contraction on the surface of the skin. This specific physical mechanism is distinct from other common topical drug classifications, such as those of anti-itch creams or antibiotic ointments.

Q: Can I take Aluboro if I am already taking over-the-counter pain relievers?

A: Official information indicates that Aluboro is associated with minimal systemic absorption when applied topically. Because the drug's action is localized, regulatory documents generally do not list systemic drug interactions with oral medications, such as over-the-counter pain relievers.

Q: Does Aluboro cause drowsiness or make you tired?

A: The documented side effects in official regulatory materials are limited to local reactions at the application site, such as temporary burning or skin irritation. Central nervous system effects like drowsiness or tiredness are not listed in the safety profile for this topical product.

Q: What happens if I forget to take a dose of Aluboro?

A: Regulatory patient information describes that the product may be used when remembered. Since the product is typically used on an as-needed basis, the application frequency should not exceed the maximum stated limit.

Q: Are there any known interactions between Aluboro and common herbal supplements?

A: The official interaction profile for Aluboro is focused primarily on other topical products that could interfere with its local action. Due to the product’s minimal systemic absorption, regulatory documents generally do not list specific interactions with herbal supplements.

Q: If Aluboro treats a chronic condition, is it meant for continuous use?

A: Aluboro is intended for short-term, acute application to weeping or irritated skin. Regulatory guidance advises discontinuing application if the treated condition or symptoms persist beyond seven days, indicating it is not meant for continuous use.

Q: Is it safe to drive or operate machinery after taking Aluboro?

A: The safety profile for Aluboro is defined by its topical use and minimal absorption into the body. It does not list side effects that are typically known to impair the cognitive or motor abilities required to drive or operate machinery.

Q: Does Aluboro contain lactose, gluten, or common allergens?

A: The active components are Aluminum Sulphate and Calcium Acetate, which react to form the solution. However, specific inactive ingredients can vary by product preparation. For individuals with concerns about allergens like lactose or gluten, reviewing the full component list on the specific product label is consistent with the contraindication for known sensitivities.

Q: Are there different forms of Aluboro (e.g., tablet, liquid, injection)?

A: Aluboro is supplied solely as a powder or tablet preparation that must be dissolved in water to create the topical solution. Regulatory information does not describe other forms, such as a ready-made liquid, injection, or pill.

Q: Are there specific symptoms that require immediate medical attention while on Aluboro?

A: Regulatory patient information indicates that signs of a serious allergic reaction require immediate attention. Official information identifies symptoms classified as a serious allergic reaction, such as rash, hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

Q: What regulatory bodies (like the FDA or EMA) have approved Aluboro?

A: In the United States, the active component is regulated by the FDA as a Generally Recognized as Safe and Effective (GRASE) Over-the-Counter (OTC) ingredient. Its established use is based on historical records and consensus reviewed by national regulatory bodies.

How should Aluboro be stored and disposed of?

How to Store and Dispose of Aluboro?

Regulatory labeling specifies strict conditions for storing Aluboro (Aluminum Acetate Powder for Topical Solution) to maintain its stability.

Storage Requirement Conditions Mandated by Labeling
Temperature Store the powder at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Protect from freezing and excessive heat.
Protection Keep the powder in a tightly sealed container, protected from moisture. The prepared solution must be protected from light.
Stability The reconstituted solution has limited use. It must generally be discarded immediately after a single use or within a maximum of 7 days, even if stored correctly.
Child Safety Store Aluboro out of the sight and reach of children and pets.

Unused or expired product must be disposed of through a drug take-back program. Disposal by flushing down the toilet or pouring down a drain is prohibited unless specified by official instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aluboro found in:

A-Z Index: